TN2011000182A1 - Live, attentuated respiratory syncytial virus - Google Patents

Live, attentuated respiratory syncytial virus

Info

Publication number
TN2011000182A1
TN2011000182A1 TN2011000182A TN2011000182A TN2011000182A1 TN 2011000182 A1 TN2011000182 A1 TN 2011000182A1 TN 2011000182 A TN2011000182 A TN 2011000182A TN 2011000182 A TN2011000182 A TN 2011000182A TN 2011000182 A1 TN2011000182 A1 TN 2011000182A1
Authority
TN
Tunisia
Prior art keywords
live
respiratory syncytial
rsv
attentuated
syncytial virus
Prior art date
Application number
TN2011000182A
Other languages
English (en)
French (fr)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TN2011000182A1 publication Critical patent/TN2011000182A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TN2011000182A 2008-11-05 2011-04-19 Live, attentuated respiratory syncytial virus TN2011000182A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05
PCT/US2009/063024 WO2010053883A1 (en) 2008-11-05 2009-11-03 Live, attentuated respiratory syncytial virus

Publications (1)

Publication Number Publication Date
TN2011000182A1 true TN2011000182A1 (en) 2012-12-17

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000182A TN2011000182A1 (en) 2008-11-05 2011-04-19 Live, attentuated respiratory syncytial virus

Country Status (19)

Country Link
US (1) US9011876B2 (enExample)
EP (1) EP2346990B1 (enExample)
JP (2) JP5016731B2 (enExample)
KR (1) KR20110063863A (enExample)
CN (1) CN102272295A (enExample)
AU (1) AU2009311287C1 (enExample)
BR (1) BRPI0921424A2 (enExample)
CA (1) CA2742086A1 (enExample)
CL (1) CL2011000999A1 (enExample)
CO (1) CO6362047A2 (enExample)
EC (1) ECSP11011033A (enExample)
IL (1) IL212437A0 (enExample)
MA (1) MA32878B1 (enExample)
MX (1) MX2011004719A (enExample)
PE (1) PE20110394A1 (enExample)
RU (1) RU2011122615A (enExample)
TN (1) TN2011000182A1 (enExample)
WO (1) WO2010053883A1 (enExample)
ZA (1) ZA201103259B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9011876B2 (en) * 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
US20140242669A1 (en) * 2011-08-18 2014-08-28 Ycine Llc Production of infectious rna viruses in yeast
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
EP4190895A1 (en) * 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
ES2854673T3 (es) * 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
CA2927431C (en) 2013-10-16 2023-10-03 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2017030997A1 (en) * 2015-08-14 2017-02-23 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered ns1 protein function and related materials and methods
EP3368547A4 (en) 2015-10-29 2019-06-05 Emory University CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
CA3075990A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2438597A (en) 1996-04-04 1997-10-29 Regents Of The University Of Michigan, The Attenuated respiratory syncytial virus
IL138681A0 (en) 1998-03-26 2001-10-31 American Cyanamid Co Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
KR100905450B1 (ko) 1999-07-09 2009-07-02 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법
AU2003295339B2 (en) 2002-09-27 2009-03-26 Medimmune, Llc Functional mutations in respiratory syncytial virus
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
CN101646768A (zh) * 2007-02-07 2010-02-10 生物载体株式会社 减毒负链rna病毒
US9011876B2 (en) * 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
CA2742086A1 (en) 2010-05-14
BRPI0921424A2 (pt) 2016-01-05
MA32878B1 (fr) 2011-12-01
CL2011000999A1 (es) 2012-07-20
AU2009311287A1 (en) 2010-05-14
PE20110394A1 (es) 2011-06-22
ECSP11011033A (es) 2011-12-30
ZA201103259B (en) 2012-01-25
JP5743794B2 (ja) 2015-07-01
AU2009311287B2 (en) 2013-02-07
CO6362047A2 (es) 2012-01-20
AU2009311287C1 (en) 2015-02-19
MX2011004719A (es) 2011-05-31
US20110212130A1 (en) 2011-09-01
IL212437A0 (en) 2011-06-30
EP2346990B1 (en) 2016-01-06
KR20110063863A (ko) 2011-06-14
CN102272295A (zh) 2011-12-07
JP2012507302A (ja) 2012-03-29
EP2346990A1 (en) 2011-07-27
JP5016731B2 (ja) 2012-09-05
WO2010053883A1 (en) 2010-05-14
US9011876B2 (en) 2015-04-21
RU2011122615A (ru) 2012-12-20
JP2011250798A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
EA201270063A1 (ru) Рекомбинантные антигены pcb
EA201070794A1 (ru) Рекомбинантные антигены rsv
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EA201592048A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
WO2010151076A3 (ko) 폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
MX2009006178A (es) Vacuna contra salmonela.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX339731B (es) Vacunas contra la bronquitis infecciosa derivadas de cepas similares a qx-bi.
GB201019240D0 (en) Respiratory syncytical virus vaccine
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
WO2010012045A8 (en) Influenza vaccines
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
EA201491969A1 (ru) Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197
BR112015012274A2 (pt) vacina, uso de bactérias de pasteurella multocida vivas atenuadas, e, método para proteger um ruminante contra pneumonia causada por bactérias de pasteurella multocida
HK1201283A1 (en) Influenza c virus and vaccine
MY158116A (en) Combination vaccine against streptococcus
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
ATE424844T1 (de) Kombinationsvakzine für geflügel
WO2011041350A3 (en) Xenotropic mulv-related virus (xmrv) compositions and methods of use
TR201905336T4 (tr) Rekombinant rsv antijenleri.